Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Archives

You are currently viewing the 2011 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EXELON

« Back to Dashboard

Summary for Tradename: EXELON

Patents:4
Applicants:1
NDAs:3
Suppliers: see list4

Pharmacology for Tradename: EXELON

Clinical Trials for: EXELON

Rivastigmine as a Treatment for Methamphetamine Dependence
Status: Completed Condition: Methamphetamine Dependence; Substance Abuse; Methamphetamine Abuse

Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
Status: Recruiting Condition: Cocaine Dependence; Cocaine Addiction; Cocaine Abuse; Substance Abuse

A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers
Status: Completed Condition: Rivastigmine Toxicity

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
Status: Completed Condition: Parkinson's Disease Dementia

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
Status: Completed Condition: Alzheimer's Disease

Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
Status: Recruiting Condition: Alzheimer's Dementia

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Status: Completed Condition: Alzheimer's Disease

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Status: Completed Condition: Alzheimer Disease

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients
Status: Completed Condition: Alzheimer Disease

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial
Status: Completed Condition: Delirium; Postoperative Cognitive Dysfunction

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
EXELON
rivastigmine tartrate
SOLUTION; ORAL021025Apr 21, 2000RXYes5,602,176<disabled><disabled>
Novartis
EXELON
rivastigmine
FILM, EXTENDED RELEASE; TRANSDERMAL022083Jul 6, 2007RXNo6,335,031<disabled>Y<disabled>
Novartis
EXELON
rivastigmine
FILM, EXTENDED RELEASE; TRANSDERMAL022083Jul 6, 2007RXYes<disabled><disabled>
Novartis
EXELON
rivastigmine tartrate
CAPSULE; ORAL020823Apr 21, 2000RXNo5,602,176<disabled><disabled>
Novartis
EXELON
rivastigmine tartrate
SOLUTION; ORAL021025Apr 21, 2000RXYes4,948,807<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EXELON

Drugname Dosage Strength RLD Submissiondate
rivastigmineTransdermal System Extended-release13.3 mg/24 hrExelon1/22/2013
rivastigmineTransdermal System Extended-release4.6 mg/24 hr and 9.5 mg/24 hrExelon Patch4/27/2011
rivastigmine tartrateOral Solution2 mg/mLExelon11/5/2004
rivastigmine tartrateCapsules1.5 mg, 3 mg, 4.5 mg and 6 mgExelon4/21/2004
« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc